Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs)
$163.48
pos +4.04
+2.53%
Today's Range: 158.60 - 164.01 | AMGN Avg Daily Volume: 4,025,100
Last Update: 12/17/14 - 4:00 PM EST
Volume: 3,412,099
YTD Performance: 39.76%
Open: $159.46
Previous Close: $159.44
52 Week Range: $108.20 - $173.14
Oustanding Shares: 760,670,000
Market Cap: 121,402,932,000
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 2 2 2 2
Hold 7 7 7 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.11 2.11 2.11 2.17
Latest Dividend: 0.61
Latest Dividend Yield: 1.53%
Dividend Ex-Date: 11/10/14
Price Earnings Ratio: 25.13
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
25.13 25.10 24.99
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.43% 42.20% 165.51%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.20 0.24 0.07
Net Income 16.90 0.10 0.03
EPS 20.30 0.40 0.12
Earnings for AMGN:
EBITDA 7.35B
Revenue 18.68B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $2.05 $2.03 $8.58 $9.41
Number of Analysts 8 2 11 9
High Estimate $2.21 $2.03 $8.75 $9.94
Low Estimate $1.96 $2.03 $8.48 $9.13
Prior Year $1.81 $1.86 $7.57 $8.58
Growth Rate (Year over Year) 13.19% 9.14% 13.37% 9.61%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Timothy Collins

 | Dec 16, 2014 | 3:48 PM EST

Why I'm looking at the iShares Biotech ETF and Amgen.

By

Jim Cramer

 | Dec 8, 2014 | 5:08 AM EST

A litany of reasons why you should calm your nerves.

By

Jim Cramer

 | Dec 2, 2014 | 11:38 AM EST

In this era of turmoil, investors can take comfort in this sector.

bullishAmgen upgraded at Nomura

Oct 29, 2014 | 6:28 AM EDT

AMGN was upgraded from Neutral to Buy, Nomura said. $193 price target. Company has cut costs and can expand the operating margin by 15 points by 2018.

By

Doug Kass

 | Oct 27, 2014 | 7:51 AM EDT
Where it began.
By

Timothy Collins

 | Oct 3, 2014 | 1:00 PM EDT

But in the longer term, I like the name as a core position.

updateMorgan Stanley Healthcare Conf.

Sep 10, 2014 | 7:39 AM EDT

Morgan Stanley Healthcare Conference

By

Timothy Collins

 | Aug 26, 2014 | 11:54 AM EDT
Checking two biotech charts.
By

Jim Cramer

 | Aug 14, 2014 | 12:18 PM EDT

Amgen's gain is pure insanity from a stock picker's point of view.

By

Jim Cramer

 | Aug 4, 2014 | 11:45 AM EDT

These quality names look appealing on the basis of 30-week moving average.

AAPL needs to clear this hurdle IF this last low is any good!!

...
The Fed didn't raise interest rates, but the market did via lower bond and note prices. Th...
WHR has regained all the of the ground lost over the last nine sessions during today's...
Just to let you know, the three dissents come from governors who will not be voting member...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.